NCT00703781已完成3 期
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 126
- 试验地点
- 1
- 主要终点
- Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero
研究概览
简要总结
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Scheduled for cataract surgery
排除标准
- •Known hypersensitivity to bromfenac and salicylates
研究组 & 干预措施
Bromfenac
Experimental
Bromfenac Ophthalmic Solution 0.09%, Dosed 1 Drop Daily
干预措施: bromfenac ophthalmic solution (Drug)
Placebo
Placebo Comparator
Placebo, Dosed 1 Drop Daily
干预措施: placebo (Drug)
结局指标
主要结局
Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero
时间窗: Day 15
Participants with SOIS of 0. Scale: 0=0 cells (complete absence); 0.5=1-5 cells (trace); 1=6-15 cells (very slight); 2=16-25 cells (moderate); 3=26-50 cells (marked); 4=\>50 cells (intense)
次要结局
- Number of Participants That Are Pain Free(Day 1)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract SurgeryCataractNCT00704418Bausch & Lomb Incorporated156
已完成
3 期
Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract SurgeryPainInflammationCataractNCT01367249Bausch & Lomb Incorporated440
已完成
3 期
Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract SurgeryPainInflammationNCT00853970Bausch & Lomb Incorporated299
已完成
2 期
Efficacy and Safety of Bromfenac Ophthalmic SolutionCataract SurgeryNCT00585975Bausch & Lomb Incorporated568
已完成
3 期
Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract SurgeryPostoperative ComplicationsCataractNCT00198445Bausch & Lomb Incorporated527